Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.
Early detection of pre-cancerous lesions or early stage pancreatic cancer seems to have a positive impact in survival for patients with an increased genetic risk to develop pancreas cancer.
In this study, following the indication of the swedish guidelines, consecutive patients with a family history for pancreas cancer underwent a clinical surveillance Magnetic Resonance Imaging (MRI) based. The results of this study were analyzed looking in the patients files collected during the screening period.
|Study Type:||Observational [Patient Registry]|
|Study Design:||Time Perspective: Prospective|
|Target Follow-Up Duration:||15 Years|
|Official Title:||Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer|
- MRI accuracy [ Time Frame: Three years ] [ Designated as safety issue: Yes ]MRI accuracy in detection precancerous pancreatic lesions.
- Definition of spectrum of precancerous pancreatic lesions [ Time Frame: During three years ] [ Designated as safety issue: Yes ]
- Outcome of surveillance program [ Time Frame: Three years ] [ Designated as safety issue: Yes ]Outcome of surveillance program analysis
Biospecimen Retention: Samples With DNA
|Study Start Date:||August 2010|
|Estimated Study Completion Date:||January 2025|
|Estimated Primary Completion Date:||January 2025 (Final data collection date for primary outcome measure)|
Familial pancreatic cancer patients
Individual with ten fold higher risk to develop pancreatic cancer.
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT02078245
|Contact: Matthias Löhr, Professor||+46 firstname.lastname@example.org|
|Contact: Marco del Chiaro, Ass prof.||+46 email@example.com|
|Gastrocentrum Karolinska University Hospital||Recruiting|
|Stockholm, Sweden, 14186|
|Contact: Matthias Löhr, Professor 08-585800000 firstname.lastname@example.org|
|Contact: Marco del Chiaro, ass prof. 08-585800000 email@example.com|
|Principal Investigator: Matthias Lohr, Professor|
|Principal Investigator:||Marco del Chiaro, ass. prof.||Karolinska University Hospital|